On June 9, 2023, Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as the "Company") participated in the second inter laboratory comparison activity for post implantation reactions of medical devices. The activity was comprehensively evaluated by experts on the project implementation plan, data analysis, and result evaluation. The company obtained a "satisfactory" evaluation result in this comparison activity.

The comparison results reflect that the company meets the relevant requirements in terms of pathological evaluation ability of reactions after medical device implantation.